These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 6998643)

  • 1. [Pharmaco-metabolic activity in chronic hepatopathies: influence of treatment with UDPG].
    Okolicsànyi L; Orlando R; Lirussi F; Naccarato R; Dal Brun G
    Clin Ter; 1980 May; 93(4):431-8. PubMed ID: 6998643
    [No Abstract]   [Full Text] [Related]  

  • 2. [Evaluation of the changes in some laboratory parameters in liver disease patients treated with Toxepasi Complex].
    Lenzi S
    Minerva Med; 1976 Sep; 67(46):2961-74. PubMed ID: 967362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatoprotective drugs. Clinical results of the use of a sulfhydryl-methylating preparation].
    Rapino P; Marulli R; Rapex G; Della Lunga S; Sabatino P
    Minerva Med; 1982 Oct; 73(40):2853-60. PubMed ID: 7133498
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of UDPG on the oxygen consumption rate in rat and pigeon liver homogenates].
    Mantiovani E; Zanardi E; Zonta N
    Atti Accad Med Lomb; 1975; 30(1-3):165-8. PubMed ID: 1234846
    [No Abstract]   [Full Text] [Related]  

  • 5. [Monooxigenase activity in liver diseases (study based on data of antipyrine metabolism)].
    Loginov AS; Bendikov EA; Kel'nia ZhA; Petrakov AV
    Ter Arkh; 1987; 59(2):84-9. PubMed ID: 3576485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical experience with silymarin in the treatment of chronic liver disease(author's transl)].
    Reutter FW; Haase W
    Schweiz Rundsch Med Prax; 1975 Sep; 64(36):1145-51. PubMed ID: 1099576
    [No Abstract]   [Full Text] [Related]  

  • 7. [Influence of UDPG, glutathione and vitamin B 12 therapy on various liver function indices in patients with liver cirrhosis].
    Coltorti M
    Clin Ter; 1975 Feb; 72(4):323-35. PubMed ID: 1222512
    [No Abstract]   [Full Text] [Related]  

  • 8. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
    Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
    Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gilbert's disease. Action of uridine diphosphoglucose on the metabolism of bilirubin].
    Ventura E; Zeneroli ML
    Med Chir Dig; 1975; 4(5-6):283-6. PubMed ID: 1207208
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of arterialization of the liver and treatment with uridine-diphospho-glucose on glucuronyl-transferase activity in rats treated with portacaval shunt].
    Okolicsanyi L; Vassanelli P; Asquini A; Merigliano S
    Boll Soc Ital Biol Sper; 1976 Apr; 52(7-8):475-9. PubMed ID: 949428
    [No Abstract]   [Full Text] [Related]  

  • 11. [Uridine-5-diphosphoglucose in the therapy of hepatopathies of diverse etiology].
    De las Casas Alonso P; Carballo García L; Silverio García C
    Rev Esp Enferm Apar Dig; 1974 Mar; 42(5):561-74. PubMed ID: 4825335
    [No Abstract]   [Full Text] [Related]  

  • 12. UDP-glucose effect on phrenic diaphragm preparation of the rat.
    Pastoris O; Raimondo S; Dossena M; Fulle D
    Farmaco Sci; 1981 Aug; 36(8):721-8. PubMed ID: 7274448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Uridine diphosphate glucose in acute viral hepatitis].
    Crispo C; Perruna F; Di Nicuolo G; Rosiello A
    Minerva Med; 1982 Feb; 73(5):187-90. PubMed ID: 7038553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
    Hayes PC; Bouchier IA
    Am J Gastroenterol; 1989 Jul; 84(7):723-6. PubMed ID: 2741882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug metabolism in patients with liver disease (author's transl)].
    Richter E; Epping J; Fuchshofen-Röckel M; Heusler H; Zilly W
    Leber Magen Darm; 1980 Oct; 10(5):234-40. PubMed ID: 7464410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Silymarin in chronic liver diseases].
    Müscher CH
    Ther Ggw; 1972 Dec; 111(12):1768-70 passim. PubMed ID: 4569030
    [No Abstract]   [Full Text] [Related]  

  • 17. Trofopar treatment of chronic liver diseases.
    Loghinov AS; Suhareva GV; Bendikov EA; Blok IE; Astasenkova CJ; Nicolaeva AP
    Rom J Intern Med; 1991; 29(1-2):65-74. PubMed ID: 1947713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Indications, method and effectiveness of immunosuppressive treatment in chronic active hepatopathies. I. Changes in the general dynamics of the disease. II. Slowing-down of the chronicization process].
    Nicolaescu T; Stoiculescu P; Bittman E; Bordeianu A; Gheorghe N; Pintilescu V; Metz L
    Med Interna (Bucur); 1974 Apr; 26(4):453-64. PubMed ID: 4839352
    [No Abstract]   [Full Text] [Related]  

  • 19. [Aminophenazone half life in patients with chronic liver parenchyma disorders].
    Ackermann E; Renger F; Dökert B; Walther M
    Z Gesamte Inn Med; 1972 Oct; 27(19):849-53. PubMed ID: 4647370
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical studies of the effect of a phosphorylated glycoderivative in acute viral hepatitis].
    Fiori GP; Mazza L
    Minerva Med; 1976 Mar; 67(12):132-40. PubMed ID: 1256689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.